AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of TRAF3-interacting protein 1 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into TRAF3-interacting protein 1 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of TRAF3-interacting protein 1, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on TRAF3-interacting protein 1. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of TRAF3-interacting protein 1. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for TRAF3-interacting protein 1 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
TRAF3-interacting protein 1
partner:
Reaxense
upacc:
Q8TDR0
UPID:
MIPT3_HUMAN
Alternative names:
Interleukin-13 receptor alpha 1-binding protein 1; Intraflagellar transport protein 54 homolog; Microtubule-interacting protein associated with TRAF3
Alternative UPACC:
Q8TDR0; Q6PCT1; Q7L8N9; Q9NRD6; Q9Y4Q1
Background:
TRAF3-interacting protein 1, also known as Interleukin-13 receptor alpha 1-binding protein 1, plays a pivotal role in inhibiting IL13 signaling, crucial for suppressing IL13-induced STAT6 phosphorylation, transcriptional activity, and DNA-binding. It is instrumental in kidney development, epithelial morphogenesis, and microtubule cytoskeleton organization, acting as a negative regulator of microtubule stability through the control of MAP4 levels.
Therapeutic significance:
Linked to Senior-Loken syndrome 9, a renal-retinal disorder, TRAF3-interacting protein 1's involvement in disease pathways underscores its potential as a target for therapeutic intervention. Understanding its role could pave the way for novel treatments for this syndrome.
